New York, NY -- October 3, 2022 -- InvestorsHub NewsWire -- via Traders News Source, a leading independent equity research and corporate access firm focused on small cap growth companies issues new research.

 

Simplicity Esports and Gaming Company (OTCQB: WINR) has entered into an exchange agreement with Diverted River Technology, LLC, in which Simplicity Esports agreed to acquire 100% of the membership interests of Diverted River in exchange for 80% of the issued and outstanding shares of Simplicity Esports’ common stock. It is expected that, Simplicity Esports’ name will be changed to Diverted River Technology, Inc., and the business of Simplicity Esports will become that of Diverted River, an ETO focused on a sustainable, high margin, recurring revenue business model. InnerScope Hearing Technologies Inc. (OTCPNK: INND) expects to benefit now that the FDA has released the "Final Rule" creating a new category of Over-the-Counter hearing aids for perceived mild to moderate hearing losses to be sold directly to consumers in retail stores, pharmacies and online without a medical exam or being fitted by a hearing healthcare professional. InnerScope, with its Network of Wholesale Retailers, believes it is well-positioned and poised to take be the leader in the new emerging OTC hearing aid market.

 

How will the WINR deal impact current stakeholders and what advantages will INND have in the OTC hearing aid market? READ MORE

 

Copy and paste to browser may be required https://tradersnewssource.com/tns-reports-new-developments/

 

Last week American Virtual Cloud Technologies, Inc. (NASDAQ: AVCT) announced that it intends to affect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock. The company's common stock is expected to begin trading on a split-adjusted basis when the market opens on October 3, 2022. AVCT operates under the Kandy brand name and operates cloud-based communications marketplaces for telecom carriers. Anavex Life Sciences Corp. (NASDAQ: AVXL) recently announced that the USPTO issued a patent to Anavex, with claims to treatment methods using its leading drug candidate, ANAVEX®2-73. The company believes that their drug candidate could treat disorders, including but not limited to, Rett syndrome, Angelman syndrome, Williams syndrome, cerebral palsy, autism spectrum disorder, and multiple sclerosis.

 

How will the AVCT reverse split impact the company and does AVXL have a blockbuster drug candidate in ANAVEX®2-73?  READ MORE

 

Copy and paste to browser may be required https://tradersnewssource.com/tns-reports-new-developments/

 

DISCLOSURE

 

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ, and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

 

PRESS RELEASE PROCEDURES

 

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. TNS LLC provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

 

NO WARRANTY

 

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://tradersnewssource.com/near-term-catalysts/.

 

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

 

Media Contact 

Mark Roberts editor@tradersnewssource.com

SOURCE: Traders News Source

Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Anavex Life Sciences Charts.
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Anavex Life Sciences Charts.